Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003


News SummaryMost relevantAll newsSector news 

MORPHOSYS : to Present at Upcoming Investor Conference

02/02/2011 | 10:05am US/Eastern

MorphoSys AG / MorphoSys to Present at Upcoming Investor Conference Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Chief Executive Officer Dr Simon Moroney will present at the upcoming Société Générale Healthcare and Biotechnology Conference in Paris.


Société Générale Healthcare and Biotechnology Conference
Date: February 9, 2011
Venue: Paris, France
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG


A PDF version of the company presentation is provided at





+++MorphoSys will publish its Full Year 2010 Results on February 24, 2011+++



About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit


HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys. arYlaTM is a trademark of MorphoSys.



This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.





For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122


Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454


Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332


Press Release:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


React to this article
Latest news on MORPHOSYS AG
02/26 MORPHOSYS : AG Reports Results for Fiscal Year 2014
02/20 MORPHOSYS : Invitation to Year End 2014 Conference Call of MorphoSys AG on 26 Fe..
02/10 MORPHOSYS : to Present at Leerink Global Healthcare Conference
01/29 MORPHOSYS : Patent Application Titled "Combinations and Uses Thereof" Published ..
01/08 MORPHOSYS : to Present at J.P. Morgan Healthcare Conference
2014 MORPHOSYS : AG: Corporate Calendar 2015
2014 MORPHOSYS : Announces Clinical Milestone in Oncology Program
2014 MORPHOSYS : and Xencor Report Final Results from Phase 1/2a Trial of Mor208
2014 MORPHOSYS : MOR208 Program Receives Positive Opinion for Orphan Medicinal Produc..
2014 MORPHOSYS : Partner Roche Provides Update on Trial of Gantenerumab in Prodromal ..
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes